On March 26, 2018, the government of Guangdong Province announced LifeTech Scientific (Shenzhen) Co., Ltd. as the winner of the first prize of the Guangdong Science and Technology Award for 2017 for its contributions to the "Establishment of a Three-level Prevention and Treatment System for Congenital Heart Diseases and Key Technology Innovations and Applications".
The project has established a province-wide congenital heart disease prevention and treatment network, pioneered the clinical application of integrated prenatal detection and postnatal treatment, and established the first domestic connected three-level congenital heart disease prevention and treatment system, which not only can significantly reduce the birth rate of children with complex congenital heart disease, but also takes a lead in advancing the prevention and treatment of congenital heart disease to the fetal period domestically. For children diagnosed with congenital heart disease, LifeTech has independently and successfully developed the world's first congenital heart disease occluder system with bioceramic coating, which greatly improves the effectiveness of the interventional treatment of congenital heart disease. Meanwhile, the R&D team has completed the implantation of the world's leading absorbable ASD occluder system into animals.
This was the fourth time that LifeTech won the Guangdong Science and Technology Award and was a reflection of LifeTech's insistence that social benefits should be placed above economic benefits, and will upgrade the diagnosis and treatment levels of congenital heart disease surgery and associated disciplines in China to the world's leading levels.